Lung Cancer Market To Cross Towering Growth Line Up To 2023 | by F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer, Merck & Co., Inc., Bristol-Myers Squibb Etc.

Lung Cancer Market - Competitive Analysis

The Lung Cancer Market is currently dominated by various players. Lung cancer has become one of the most common causes of cancer death worldwide. So, in recent years various existing and new marketers are continuously coming up with innovative products to control this condition.

Key Players:

Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Pfizer (US), Merck & Co., Inc. (US), Bristol-Myers Squibb (US), Eli Lilly and Company (US), and Sanofi (France) are some of the prominent players at the forefront of competition in the lung cancer market and are profiled in MRFR Analysis.
Lung Cancer Market - Segmentation

Global Lung Cancer Market has been segmented on the basis of types which comprises of push button Lung Cancer, pressure activated Lung Cancer and side button Lung Cancer. On the basis of end user, it comprises of hospitals & clinics, diagnostic centers and pathology laboratories, home diagnostics and other end users.

Get Sample report @ https://www.marketresearchfuture.com/sample_request/1185

Lung Cancer Market – Highlights

Lung Cancer has been found to be one of the leading causes of cancer-related mortality as compared to other types of cancer. This has led to high demand for effective treatment options that assist in remission or allow prolonging of life while keeping the quality of life intact. Market Research Future's (MRFR), latest market report on the Global Lung Cancer Market, has disclosed an estimated evaluation of USD 36.92 billion by the end of 2023 and a considerable CAGR of 13.5% during the forecast period 2017-2023.

The market has been growing at a steady pace over the past few years and is expected to continue to do so as there has been very little difference in the smoking habits of the global population. The World Cancer Research Fund International has found that smoking is responsible for approximately 85% of all types of lung cancer. Rising cases of infections, increased awareness & early diagnoses are other factors that drive the growth of this market.

The market is not without challenges and restraints, despite rapid growth. Low rates of remission, side effects associated with treatment, increased the incidence of fast-growing lung cancer and decreased the quality of life of late-stage cancer patients are some restraints that are likely to affect market growth. However, ongoing research & development of treatment options, the vast demand for the same and the encouragement and support from government and other regulatory bodies is expected to encourage growth for the market during the forecast period. Moreover, there has been growing interest in using genetic therapies to treat lung cancer with utmost efficiency, the unrealized potential of this opportunity is expected to motivate robust growth for the global lung cancer market.

Industry News:

Hoffmann-La Roche Ltd, a Switzerland based company, manufactures various cancer treatment products such as anti-bcl-2 (SP66) Rabbit Monoclonal Primary Antibody, anti-c-MYC (Y69) Rabbit Monoclonal Primary Antibody, anti-CD7 (SP94) Rabbit Monoclonal Primary Antibody, anti-CEA (TF 3H8-1) Primary Antibody, anti-Cytokeratin 5/6 (D5/16B4) Mouse Monoclonal Primary Antibody, anti-E-cadherin (EP700Y) Rabbit Monoclonal Primary Antibody, and others. In the year 2013, Roche received FDA approval for Tarceva (erlotinib) tablets and cobas EGFR Mutation Test for specific type of lung cancer.

Pfizer is another US based renowned bio pharmaceutical organization. In July 2016, Pfizer and Western Oncolytics announce immuno-oncology research collaboration. This collaboration has the aim to investigate novel oncolytic virus technology. Under terms of agreement, Pfizer and Western Oncolytics will collaborate on preclinical, clinical development of WO-12 through Phase I trials. Financial terms of agreement are not disclosed.

AstraZeneca's new cancer drug, Imfinzi has shown definitive results that prove it is successful in extending the life expectancy in lung cancer patients with inoperable stage III NSCLC. Moreover, the drug offers patients progression-free survival at an average of 16.8 months. The success of the clinical trials has prompted U.S.A and Canada regulation authorities to approve Imfinzi.

Merck & Co. has had success in trials of its oncology drug Keytruda which is already being used to treat several types of cancer. Most recently, it has shown the ability to work successfully as a first-line treatment combined with chemotherapy for mNSCLC in late-stage lung cancer patients.

Browse Complete 102 Pages Premium Research Report Enabled with Tables and Figures @ https://www.marketresearchfuture.com/reports/lung-cancer-market-1185

Lung Cancer Market - Regional Analysis

The Global Market for Lung Cancer is growing steadily. The global lung cancer market on the basis of region comprises of North America, Europe, Asia Pacific and Middle East & Africa. The global market for Lung Cancer is growing with the CAGR of 13.5% during the forecast period from 2017-2023. NSCLC is the most common type of lung cancer globally. The global Lung Cancer market reached USD 36929.8 million in 2023 from 15219.7 million in 2016. Europe region captured the second largest market globally and is expected to reach USD 8,536.3 million by 2023 due to the growing demand and need for lung cancer drugs, and the growing prevalence of lung cancer.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: salesteam@marketresearchfuture.com

This release was published on openPR.